BRPI0510310A - oral formulation for poorly absorbed drug application - Google Patents

oral formulation for poorly absorbed drug application

Info

Publication number
BRPI0510310A
BRPI0510310A BRPI0510310-0A BRPI0510310A BRPI0510310A BR PI0510310 A BRPI0510310 A BR PI0510310A BR PI0510310 A BRPI0510310 A BR PI0510310A BR PI0510310 A BRPI0510310 A BR PI0510310A
Authority
BR
Brazil
Prior art keywords
drug
illustrative
oral formulation
poorly absorbed
enhancer
Prior art date
Application number
BRPI0510310-0A
Other languages
Portuguese (pt)
Inventor
Seung-Ho Choi
Seong-Wan Cho
Original Assignee
Procarrier Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040029465A external-priority patent/KR20050104152A/en
Application filed by Procarrier Inc filed Critical Procarrier Inc
Publication of BRPI0510310A publication Critical patent/BRPI0510310A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAçãO ORAL PARA APLICAçãO DE DROGAS FRACAMENTE ABSORVIDAS. A presente invenção refere-se a uma composição para aplicação oral de um fármaco fracamente absorvido. A composição inclui o fármaco, um intensificador para aumentar a absorção do fármaco através da mucosa intestinal, um promotor que, sozinho, não aumenta a absorção do fármaco através da mucosa intestinal, mas que também aumenta a absorção do fármaco na presença do intensificador e opcionalmente um protetor para proteger a fármaco de decomposição física ou química ou da inativação no trato gastrointestinal. Intensificadores ilustrativos incluem ésteres de ácido graxo de sacarose e os promotores ilustrativos incluem aminoaçúcares e derivados de aminoácido, tais como poli (aminoácidos). Protetores ilustrativos incluem metilcelulose, álcool polivinílico e polivinil pirrolidona.ORAL FORMULATION FOR APPLICATION OF WEAKLY ABSORBED DRUGS. The present invention relates to a composition for oral application of a poorly absorbed drug. The composition includes the drug, an enhancer for enhancing drug absorption through the intestinal mucosa, a promoter that alone does not increase drug absorption through the intestinal mucosa, but which also increases drug absorption in the presence of the enhancer and optionally. a protector to protect the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters and illustrative promoters include amino sugars and amino acid derivatives such as poly (amino acids). Illustrative protectors include methylcellulose, polyvinyl alcohol and polyvinyl pyrrolidone.

BRPI0510310-0A 2004-04-28 2005-04-28 oral formulation for poorly absorbed drug application BRPI0510310A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020040029465A KR20050104152A (en) 2004-04-28 2004-04-28 Enhancing systems for poorly absorptive drugs
US10/973,644 US7666446B2 (en) 2004-04-28 2004-10-25 Oral formulation for delivery of poorly absorbed drugs
PCT/US2005/014409 WO2005105050A1 (en) 2004-04-28 2005-04-28 Oral formulation for delivery of poorly absorbed drugs

Publications (1)

Publication Number Publication Date
BRPI0510310A true BRPI0510310A (en) 2007-10-16

Family

ID=35241410

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510310-0A BRPI0510310A (en) 2004-04-28 2005-04-28 oral formulation for poorly absorbed drug application

Country Status (7)

Country Link
EP (1) EP1744731A1 (en)
JP (1) JP2007535545A (en)
AU (1) AU2005237580B2 (en)
BR (1) BRPI0510310A (en)
CA (1) CA2595116A1 (en)
MX (1) MXPA06012489A (en)
WO (1) WO2005105050A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
US8415401B2 (en) * 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
RU2519193C2 (en) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Improving absorption of therapeutic agents through mucous membranes or skin
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN102145172B (en) * 2011-01-28 2012-09-26 瑞普（天津）生物药业有限公司 Composition for improving absorbance of aminoglycoside drug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56140924A (en) * 1980-04-04 1981-11-04 Teijin Ltd Calcitonin pharmaceutical preparation
CH667994A5 (en) * 1986-05-27 1988-11-30 Sandoz Ag Pharmaceutical compsns.
JP2688266B2 (en) * 1989-02-22 1997-12-08 株式会社三和化学研究所 Pharmaceutical composition having aldose reductase inhibitory action and good absorbability
TW209174B (en) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
JPH11292787A (en) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
EP1024808A1 (en) * 1998-04-11 2000-08-09 Errekappa Euroterapici S.p.a. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
US6638534B1 (en) * 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US20030195179A1 (en) * 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption

Also Published As

Publication number Publication date
AU2005237580A1 (en) 2005-11-10
AU2005237580B2 (en) 2011-06-16
JP2007535545A (en) 2007-12-06
MXPA06012489A (en) 2007-02-08
WO2005105050A1 (en) 2005-11-10
CA2595116A1 (en) 2005-11-10
EP1744731A1 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
BRPI0607549A2 (en) pharmaceutical delivery systems for hydrophobic drugs and compositions comprising the same
BRPI0924460A2 (en) pharmaceutical composition for use in medical and veterinary ophthalmology
BRPI0510310A (en) oral formulation for poorly absorbed drug application
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
CY1115289T1 (en) Methods of Treatment Against Inflammation-Related Illness
CY1113269T1 (en) INDIAZOLYL AMID PRODUCT FOR THE THERAPEUTIC TREATMENT OF GLUCCORTIC MEDICINES
BRPI0615145A2 (en) xanthine derivatives as selective hm74a agonists
BRPI0720220B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising it
BRPI0514098A (en) pharmaceutical formulation
BRPI0517458A (en) xanthine derivatives with hm74a receptor activity
CO6251277A2 (en) INHIBITOR OF THE DPP-IV COMBINED WITH MORE THAN AN ANTI-DIABETIC AGENT, TABLETS THAT INCLUDE SUCH FORMULATIONS, ITS USE AND PROCEDURES FOR THEIR PREPARATION.
DE602006014990D1 (en) INTRANASAL ADMINISTRATION OF FAST-ACTING INSULIN
NO20073722L (en) Pharmaceutical-like compositions comprising bendamustine
BR122017015098B8 (en) immediate release pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
BRPI0707235B8 (en) sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation
WO2007138116A3 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
BRPI0714803B8 (en) smac peptidomimetic compounds, their uses, and pharmaceutical composition
HRP20130406T1 (en) Medicaments with hm74a receptor activity
NO20073601L (en) Immunresponsmodifikator foam formulations
RS20070318A (en) Sterile formulations of modifier of immune response and processes
BRPI0620229B8 (en) pharmaceutical formulations and production processes of said formulations
CU23734A1 (en) IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
NO20080220L (en) Formulations with high drug loading and dosage forms
EA200970081A1 (en) COMPOUNDS WITH POTENTIAL ACTIONS WITH RESPECT TO ETIONMIDE ACTIVITY AND THEIR USE
WO2007128086A3 (en) Novel viral replication inhibitor

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.